Serono Rebif Reps Will Add Amgen Novantrone Via License Deal For MS Drug
Executive Summary
Amgen's Novantrone will be detailed by Serono's Rebif multiple sclerosis sales reps under a licensing agreement announced Nov. 13
You may also be interested in...
OSI will market Novantrone for cancer
OSI will use a contract sales organization to market Novantrone for acute nonlymphocytic leukemia after licensing oncologic use of mitoxantrone from Serono. The product will allow OSI to build a sales force and experience in oncology field; the firm's lead R&D project is the oncologic Tarceva. OSI will be the fifth company to market Novantrone. The drug was developed by Lederle, licensed to Immunex, briefly owned by Amgen after it acquired Immunex, and licensed to Serono in November (1"The Pink Sheet" Nov. 18, 2002, p. 32). Serono will continue to market Novantrone for multiple sclerosis and book all U.S. sales for all indications...
OSI will market Novantrone for cancer
OSI will use a contract sales organization to market Novantrone for acute nonlymphocytic leukemia after licensing oncologic use of mitoxantrone from Serono. The product will allow OSI to build a sales force and experience in oncology field; the firm's lead R&D project is the oncologic Tarceva. OSI will be the fifth company to market Novantrone. The drug was developed by Lederle, licensed to Immunex, briefly owned by Amgen after it acquired Immunex, and licensed to Serono in November (1"The Pink Sheet" Nov. 18, 2002, p. 32). Serono will continue to market Novantrone for multiple sclerosis and book all U.S. sales for all indications...
Serono/Pfizer Rebif Co-Promotion Deal Will Use Neurontin Sales Force
Pfizer's Neurontin sales force will co-promote Serono's multiple sclerosis drug Rebif under an agreement announced by the two companies July 11